Skip to main content
The EMBO Journal logoLink to The EMBO Journal
. 1999 Jun 15;18(12):3348–3358. doi: 10.1093/emboj/18.12.3348

The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing.

H Waterman 1, I Alroy 1, S Strano 1, R Seger 1, Y Yarden 1
PMCID: PMC1171415  PMID: 10369675

Abstract

Signaling by the epidermal growth factor (EGF) family and the neuregulin group of ligands is mediated by four ErbB receptor tyrosine kinases, that form homo- and heterodimeric complexes. Paradoxically, the neuregulin receptor ErbB-3 is devoid of catalytic activity, but its heterodimerization with other ErbBs, particularly the ligand-less ErbB-2 oncoprotein of carcinomas, reconstitutes superior mitogenic and transforming activities. To understand the underlying mechanism we constructed a chimeric EGF-receptor (ErbB-1) whose autophosphorylation C-terminal domain was replaced by the corresponding portion of ErbB-3. Consistent with the possibility that this domain recruits a relatively potent signaling pathway(s), the mitogenic signals generated by the recombinant fusion protein were superior to those generated by ErbB-1 homodimers and comparable to the proliferative activity of ErbB-2/ErbB-3 heterodimers. Upon ligand binding, the chimeric receptor recruited an ErbB-3-specific repertoire of signaling proteins, including Shc and the phosphatidylinositol 3-kinase, but excluding the ErbB-1-specific substrate, phospholipase Cgamma1. Unlike ErbB-1, which is destined to lysosomal degradation through a mechanism that includes recruitment of c-Cbl and receptor poly-ubiquitination, the C-terminal tail of ErbB-3 shunted the chimeric protein to the ErbB-3-characteristic recycling pathway. These observations attribute the mitogenic superiority of ErbB-3 to its C-terminal tail and imply that the flanking kinase domain has lost catalytic activity in order to restrain the relatively potent signaling capability of the C-terminus.

Full Text

The Full Text of this article is available as a PDF (351.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alimandi M., Romano A., Curia M. C., Muraro R., Fedi P., Aaronson S. A., Di Fiore P. P., Kraus M. H. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene. 1995 May 4;10(9):1813–1821. [PubMed] [Google Scholar]
  2. Alimandi M., Wang L. M., Bottaro D., Lee C. C., Kuo A., Frankel M., Fedi P., Tang C., Lippman M., Pierce J. H. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors. EMBO J. 1997 Sep 15;16(18):5608–5617. doi: 10.1093/emboj/16.18.5608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Alroy I., Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 1997 Jun 23;410(1):83–86. doi: 10.1016/s0014-5793(97)00412-2. [DOI] [PubMed] [Google Scholar]
  4. Barbacci E. G., Guarino B. C., Stroh J. G., Singleton D. H., Rosnack K. J., Moyer J. D., Andrews G. C. The structural basis for the specificity of epidermal growth factor and heregulin binding. J Biol Chem. 1995 Apr 21;270(16):9585–9589. doi: 10.1074/jbc.270.16.9585. [DOI] [PubMed] [Google Scholar]
  5. Baulida J., Kraus M. H., Alimandi M., Di Fiore P. P., Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem. 1996 Mar 1;271(9):5251–5257. doi: 10.1074/jbc.271.9.5251. [DOI] [PubMed] [Google Scholar]
  6. Ben-Levy R., Paterson H. F., Marshall C. J., Yarden Y. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J. 1994 Jul 15;13(14):3302–3311. doi: 10.1002/j.1460-2075.1994.tb06632.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bray D. Intracellular signalling as a parallel distributed process. J Theor Biol. 1990 Mar 22;143(2):215–231. doi: 10.1016/s0022-5193(05)80268-1. [DOI] [PubMed] [Google Scholar]
  8. Burden S., Yarden Y. Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron. 1997 Jun;18(6):847–855. doi: 10.1016/s0896-6273(00)80324-4. [DOI] [PubMed] [Google Scholar]
  9. Carpenter C. L., Cantley L. C. Phosphoinositide 3-kinase and the regulation of cell growth. Biochim Biophys Acta. 1996 Aug 8;1288(1):M11–M16. doi: 10.1016/0304-419x(96)00018-2. [DOI] [PubMed] [Google Scholar]
  10. Carraway K. L., 3rd, Cantley L. C. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell. 1994 Jul 15;78(1):5–8. doi: 10.1016/0092-8674(94)90564-9. [DOI] [PubMed] [Google Scholar]
  11. Chen X., Levkowitz G., Tzahar E., Karunagaran D., Lavi S., Ben-Baruch N., Leitner O., Ratzkin B. J., Bacus S. S., Yarden Y. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J Biol Chem. 1996 Mar 29;271(13):7620–7629. [PubMed] [Google Scholar]
  12. Cohen B. D., Kiener P. A., Green J. M., Foy L., Fell H. P., Zhang K. The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J Biol Chem. 1996 Nov 29;271(48):30897–30903. doi: 10.1074/jbc.271.48.30897. [DOI] [PubMed] [Google Scholar]
  13. Ebner R., Derynck R. Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes. Cell Regul. 1991 Aug;2(8):599–612. doi: 10.1091/mbc.2.8.599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Erickson S. L., O'Shea K. S., Ghaboosi N., Loverro L., Frantz G., Bauer M., Lu L. H., Moore M. W. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development. 1997 Dec;124(24):4999–5011. doi: 10.1242/dev.124.24.4999. [DOI] [PubMed] [Google Scholar]
  15. Fedi P., Pierce J. H., di Fiore P. P., Kraus M. H. Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol. 1994 Jan;14(1):492–500. doi: 10.1128/mcb.14.1.492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fiddes R. J., Campbell D. H., Janes P. W., Sivertsen S. P., Sasaki H., Wallasch C., Daly R. J. Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3. J Biol Chem. 1998 Mar 27;273(13):7717–7724. doi: 10.1074/jbc.273.13.7717. [DOI] [PubMed] [Google Scholar]
  17. Galcheva-Gargova Z., Theroux S. J., Davis R. J. The epidermal growth factor receptor is covalently linked to ubiquitin. Oncogene. 1995 Dec 21;11(12):2649–2655. [PubMed] [Google Scholar]
  18. Graus-Porta D., Beerli R. R., Daly J. M., Hynes N. E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997 Apr 1;16(7):1647–1655. doi: 10.1093/emboj/16.7.1647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Guy P. M., Platko J. V., Cantley L. C., Cerione R. A., Carraway K. L., 3rd Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8132–8136. doi: 10.1073/pnas.91.17.8132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Johansen F. E., Prywes R. Two pathways for serum regulation of the c-fos serum response element require specific sequence elements and a minimal domain of serum response factor. Mol Cell Biol. 1994 Sep;14(9):5920–5928. doi: 10.1128/mcb.14.9.5920. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Joly M., Kazlauskas A., Fay F. S., Corvera S. Disruption of PDGF receptor trafficking by mutation of its PI-3 kinase binding sites. Science. 1994 Feb 4;263(5147):684–687. doi: 10.1126/science.8303278. [DOI] [PubMed] [Google Scholar]
  22. Karunagaran D., Tzahar E., Beerli R. R., Chen X., Graus-Porta D., Ratzkin B. J., Seger R., Hynes N. E., Yarden Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J. 1996 Jan 15;15(2):254–264. [PMC free article] [PubMed] [Google Scholar]
  23. Kim H. H., Vijapurkar U., Hellyer N. J., Bravo D., Koland J. G. Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem J. 1998 Aug 15;334(Pt 1):189–195. doi: 10.1042/bj3340189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kornfeld K. Vulval development in Caenorhabditis elegans. Trends Genet. 1997 Feb;13(2):55–61. doi: 10.1016/s0168-9525(97)01005-6. [DOI] [PubMed] [Google Scholar]
  25. Levkowitz G., Klapper L. N., Tzahar E., Freywald A., Sela M., Yarden Y. Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene. 1996 Mar 7;12(5):1117–1125. [PubMed] [Google Scholar]
  26. Levkowitz G., Waterman H., Zamir E., Kam Z., Oved S., Langdon W. Y., Beguinot L., Geiger B., Yarden Y. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 1998 Dec 1;12(23):3663–3674. doi: 10.1101/gad.12.23.3663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Marikovsky M., Lavi S., Pinkas-Kramarski R., Karunagaran D., Liu N., Wen D., Yarden Y. ErbB-3 mediates differential mitogenic effects of NDF/heregulin isoforms on mouse keratinocytes. Oncogene. 1995 Apr 6;10(7):1403–1411. [PubMed] [Google Scholar]
  28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  29. Mossie K., Jallal B., Alves F., Sures I., Plowman G. D., Ullrich A. Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine kinase family. Oncogene. 1995 Nov 16;11(10):2179–2184. [PubMed] [Google Scholar]
  30. Obermeier A., Tinhofer I., Grunicke H. H., Ullrich A. Transforming potentials of epidermal growth factor and nerve growth factor receptors inversely correlate with their phospholipase C gamma affinity and signal activation. EMBO J. 1996 Jan 2;15(1):73–82. [PMC free article] [PubMed] [Google Scholar]
  31. Olayioye M. A., Graus-Porta D., Beerli R. R., Rohrer J., Gay B., Hynes N. E. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol. 1998 Sep;18(9):5042–5051. doi: 10.1128/mcb.18.9.5042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Peles E., Ben-Levy R., Tzahar E., Liu N., Wen D., Yarden Y. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J. 1993 Mar;12(3):961–971. doi: 10.1002/j.1460-2075.1993.tb05737.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Pinkas-Kramarski R., Lenferink A. E., Bacus S. S., Lyass L., van de Poll M. L., Klapper L. N., Tzahar E., Sela M., van Zoelen E. J., Yarden Y. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin. Oncogene. 1998 Mar 12;16(10):1249–1258. doi: 10.1038/sj.onc.1201642. [DOI] [PubMed] [Google Scholar]
  34. Pinkas-Kramarski R., Soussan L., Waterman H., Levkowitz G., Alroy I., Klapper L., Lavi S., Seger R., Ratzkin B. J., Sela M. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 1996 May 15;15(10):2452–2467. [PMC free article] [PubMed] [Google Scholar]
  35. Prigent S. A., Gullick W. J. Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 1994 Jun 15;13(12):2831–2841. doi: 10.1002/j.1460-2075.1994.tb06577.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Riethmacher D., Sonnenberg-Riethmacher E., Brinkmann V., Yamaai T., Lewin G. R., Birchmeier C. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature. 1997 Oct 16;389(6652):725–730. doi: 10.1038/39593. [DOI] [PubMed] [Google Scholar]
  37. Seger R., Krebs E. G. The MAPK signaling cascade. FASEB J. 1995 Jun;9(9):726–735. [PubMed] [Google Scholar]
  38. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177–182. doi: 10.1126/science.3798106. [DOI] [PubMed] [Google Scholar]
  39. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707–712. doi: 10.1126/science.2470152. [DOI] [PubMed] [Google Scholar]
  40. Sliwkowski M. X., Schaefer G., Akita R. W., Lofgren J. A., Fitzpatrick V. D., Nuijens A., Fendly B. M., Cerione R. A., Vandlen R. L., Carraway K. L., 3rd Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem. 1994 May 20;269(20):14661–14665. [PubMed] [Google Scholar]
  41. Soltoff S. P., Carraway K. L., 3rd, Prigent S. A., Gullick W. G., Cantley L. C. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol. 1994 Jun;14(6):3550–3558. doi: 10.1128/mcb.14.6.3550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Sorkin A., Di Fiore P. P., Carpenter G. The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired. Oncogene. 1993 Nov;8(11):3021–3028. [PubMed] [Google Scholar]
  43. Sorkin A., Waters C. M. Endocytosis of growth factor receptors. Bioessays. 1993 Jun;15(6):375–382. doi: 10.1002/bies.950150603. [DOI] [PubMed] [Google Scholar]
  44. Syroid D. E., Maycox P. R., Burrola P. G., Liu N., Wen D., Lee K. F., Lemke G., Kilpatrick T. J. Cell death in the Schwann cell lineage and its regulation by neuregulin. Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9229–9234. doi: 10.1073/pnas.93.17.9229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Thien C. B., Langdon W. Y. c-Cbl: a regulator of T cell receptor-mediated signalling. Immunol Cell Biol. 1998 Oct;76(5):473–482. doi: 10.1046/j.1440-1711.1998.00768.x. [DOI] [PubMed] [Google Scholar]
  46. Tzahar E., Moyer J. D., Waterman H., Barbacci E. G., Bao J., Levkowitz G., Shelly M., Strano S., Pinkas-Kramarski R., Pierce J. H. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J. 1998 Oct 15;17(20):5948–5963. doi: 10.1093/emboj/17.20.5948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Tzahar E., Pinkas-Kramarski R., Moyer J. D., Klapper L. N., Alroy I., Levkowitz G., Shelly M., Henis S., Eisenstein M., Ratzkin B. J. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J. 1997 Aug 15;16(16):4938–4950. doi: 10.1093/emboj/16.16.4938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Tzahar E., Waterman H., Chen X., Levkowitz G., Karunagaran D., Lavi S., Ratzkin B. J., Yarden Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 1996 Oct;16(10):5276–5287. doi: 10.1128/mcb.16.10.5276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Tzahar E., Yarden Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta. 1998 Feb 20;1377(1):M25–M37. doi: 10.1016/s0304-419x(97)00032-2. [DOI] [PubMed] [Google Scholar]
  50. Vartanian T., Goodearl A., Viehöver A., Fischbach G. Axonal neuregulin signals cells of the oligodendrocyte lineage through activation of HER4 and Schwann cells through HER2 and HER3. J Cell Biol. 1997 Apr 7;137(1):211–220. doi: 10.1083/jcb.137.1.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Vieira A. V., Lamaze C., Schmid S. L. Control of EGF receptor signaling by clathrin-mediated endocytosis. Science. 1996 Dec 20;274(5295):2086–2089. doi: 10.1126/science.274.5295.2086. [DOI] [PubMed] [Google Scholar]
  52. Vijapurkar U., Cheng K., Koland J. G. Mutation of a Shc binding site tyrosine residue in ErbB3/HER3 blocks heregulin-dependent activation of mitogen-activated protein kinase. J Biol Chem. 1998 Aug 14;273(33):20996–21002. doi: 10.1074/jbc.273.33.20996. [DOI] [PubMed] [Google Scholar]
  53. Wallasch C., Weiss F. U., Niederfellner G., Jallal B., Issing W., Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 1995 Sep 1;14(17):4267–4275. doi: 10.1002/j.1460-2075.1995.tb00101.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Waterman H., Sabanai I., Geiger B., Yarden Y. Alternative intracellular routing of ErbB receptors may determine signaling potency. J Biol Chem. 1998 May 29;273(22):13819–13827. doi: 10.1074/jbc.273.22.13819. [DOI] [PubMed] [Google Scholar]
  55. Wells A., Welsh J. B., Lazar C. S., Wiley H. S., Gill G. N., Rosenfeld M. G. Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science. 1990 Feb 23;247(4945):962–964. doi: 10.1126/science.2305263. [DOI] [PubMed] [Google Scholar]
  56. Whitmarsh A. J., Shore P., Sharrocks A. D., Davis R. J. Integration of MAP kinase signal transduction pathways at the serum response element. Science. 1995 Jul 21;269(5222):403–407. doi: 10.1126/science.7618106. [DOI] [PubMed] [Google Scholar]
  57. Yano S., Tokumitsu H., Soderling T. R. Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway. Nature. 1998 Dec 10;396(6711):584–587. doi: 10.1038/25147. [DOI] [PubMed] [Google Scholar]
  58. Yoon C. H., Lee J., Jongeward G. D., Sternberg P. W. Similarity of sli-1, a regulator of vulval development in C. elegans, to the mammalian proto-oncogene c-cbl. Science. 1995 Aug 25;269(5227):1102–1105. doi: 10.1126/science.7652556. [DOI] [PubMed] [Google Scholar]
  59. Zhang K., Sun J., Liu N., Wen D., Chang D., Thomason A., Yoshinaga S. K. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem. 1996 Feb 16;271(7):3884–3890. [PubMed] [Google Scholar]
  60. Zhu X., Lai C., Thomas S., Burden S. J. Neuregulin receptors, erbB3 and erbB4, are localized at neuromuscular synapses. EMBO J. 1995 Dec 1;14(23):5842–5848. doi: 10.1002/j.1460-2075.1995.tb00272.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. van der Geer P., Hunter T., Lindberg R. A. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol. 1994;10:251–337. doi: 10.1146/annurev.cb.10.110194.001343. [DOI] [PubMed] [Google Scholar]

Articles from The EMBO Journal are provided here courtesy of Nature Publishing Group

RESOURCES